StreetInsider.com News Articles

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

BAD HOMBURG, Germany, May 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Thu, 23 May 2024 12:33:00 -0400

The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating
FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress
Solid deleveraging prospects

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

BAD HOMBURG, Germany, May 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61^st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm,

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Tue, 21 May 2024 10:00:00 -0400

Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence
Company-wide experts highlight robust anonymized dialysis database
CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented